LianBio is a biotechnology company focused on bringing paradigm-shifting medicines to patients through partnerships that provide access to the best science-driven therapeutic discoveries.
Location: China, Shanghai
Total raised: $635M
Investors 4
| Date | Name | Website |
| 21.02.2021 | Logos Capi... | logoscapit... |
| - | RA Capital... | racap.com |
| - | Perceptive... | perceptive... |
| 02.11.2022 | Xontogeny | xontogeny.... |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 01.11.2021 | IPO | $325M | - |
| 29.10.2020 | - | $310M | - |
Mentions in press and media 7
| Date | Title | Description |
| 25.11.2024 | Ascentage Pharma Appoints Ms. Marina S. Bozilenko and Dr. Debra Yu as Independent Non-Executive Directors | ROCKVILLE, Md. and SUZHOU, China, Nov. 25, 2024 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in discovering, developing and commercializing therapies to address global unmet medical needs primarily ... |
| 12.05.2023 | LianBio Announces Marketing Approval of CAMZYOS® (mavacamten) in the Macau Special Administrative Region (SAR) of China | SHANGHAI, CHINA, and PRINCETON, N. J., USA – Media OutReach – 12 May 2023 – LianBio (Nasdaq: LIAN), a biotechnology company dedicated to bringing innovative medicines to patients in China and other major Asian markets, announced yesterday t... |
| 07.09.2022 | NANOBIOTIX与联拓生物宣布，用于评估NBTXR3治疗头颈癌的NANORAY-312 III期试验在亚洲完成首位患者招募 | 针对Nanobiotix治疗头颈癌的关键性III期试验,其区域启动工作按计划推进，联拓生物在亚洲完成首位患者招募此项合作继续增强联拓生物在亚洲的行业领导地位，同时，Nanobiotix将继续专注于计划中的市场启动和全球招募 巴黎（法国）、剑桥（美国马萨诸塞州）、上海（中国）和普林斯顿（美国新泽西州), Sept. 08, 2022 (GLOBE NEWSWIRE) -- NANOBIOTIX（泛欧交易所：NANO；纳斯达克：NBTX）是一家处于临床后期开发阶段的生物技术公司，... |
| 01.11.2021 | China-Focused Biotech LianBio Raises $325 Million in U.S. IPO China-Focused Biotech LianBio Raises $325 Million in U.S. IPO | (Bloomberg) -- Biotechnology firm LianBio raised $325 million in an initial public offering, according to a statement, potentially opening a narrow path for U.S. listings by companies operating primarily in China. The company sold 20.3 mill... |
| 29.10.2020 | LianBio Raises $310 Million Crossover Financing | SHANGHAI & PRINCETON, N.J.--(BUSINESS WIRE)--LianBio, a Chinese company focused on bringing paradigm-shifting medicines to patients in China and major Asian markets, today announced it has raised $310 million in an oversubscribed crosso... |
| 29.10.2020 | LianBio Announces $310 Million Crossover Financing | - |
| 29.10.2020 | LianBio : Announces $310 Million Crossover Financing | LianBio, a Chinese company focused on bringing paradigm-shifting medicines to patients in China and major Asian markets, today announced it has raised $310 million in an oversubscribed crossover financing, following its founding and initial... |